Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.…
Tactile Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference
Tactile Systems Technology (NASDAQ: TCMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,086 employees.
The shares were at 25.60 USD on 20 November 2026, up 7.2% over 52 weeks. Its 52-week range is 20.53 USD to 37.77 USD: the price is 32.2% below the high and 24.7% above the low.
At a market capitalisation of 573.48M USD, it trades at 24.9 times trailing earnings and 17.4 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, so TCMD is valued in line with them.
Tactile Systems Technology reports return on equity of 8.7%, an operating margin of 9.4% and revenue up 7.1% year over year.
It holds more cash than debt, a net cash position of 58.04M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 3 analysts cover the stock; their mean price target of 36.33 USD is 41.9% above the current price. The next earnings report is expected on 18 February 2027.